Another strong quarter has Cantor Fitzgerald Canada analyst Scott Curtis feeling bullish about BioSyent (TSXV:RX). On Wednesday, BioSyent reported … [Read more...] about BioSyent is firing on all cylinders, says Cantor Fitzgerald Canada
The current weakness in shares of BioSysent (TSXV:RX) is a buying opportunity, says Cantor Fitzgerald Canada analyst Scott Curtis. In a research … [Read more...] about Buy BioSyent on weakness, says Cantor Fitzgerald Canada
BioSyent (TSXV:RX) today announced Q2 results that are indicative of the revenue and earnings momentum investors have to come to expect from this … [Read more...] about BioSyent Keeps Momentum Going with Solid Q2 Earnings
It was around 1999, and I was a pharmaceutical sales rep with Fournier Pharma, when I bumped into my first Paladin Labs sales rep at a physician’s … [Read more...] about Is BioSyent The Next Paladin Labs?
September has always had that "back to school" feeling in the capital markets as, for better or worse, share volume begins to return after fund … [Read more...] about Five TSX Techs Trading at or near 52 week Highs